ArticleEuropean spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society2026
Primary spinal cord malignant B-cell lymphoma successfully treated with tirabrutinib at relapse: a case report.
Article in European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePrimary spinal cord lymphoma rarely occurs, and the treatment strategy has not been standardized. Tirabrutinib (TIR) shows therapeutic efficacy for cases with primary central nervous system lymphoma (PCNSL) with B-cell pathology arising intracranially, but the evidence for primary spinal cord cases has not been reported. We present a case of primary spinal cord lymphoma successfully treated with TIR at relapse.
methodsCase report.
resultsA 58-year-old male presented with progressive numbness from the neck down and neck pain. Magnetic resonance imaging revealed an intramedullary lesion in the cervical spine from the cervico–medullary junction to the C7. Biopsy was performed, and the pathological diagnosis was diffuse large B-cell lymphoma. Four cycles of chemotherapy with rituximab, methotrexate, procarbazine, and vincristine (R-MPV) were ineffective, but remission of the cervical lesion was achieved after subsequent irradiation. However, after 1 month, a de novo lesion was observed in the lower thoracic spinal cord. Tumor remission was achieved with TIR, and the patient showed no relapse for 42 months after starting TIR.
conclusionTIR administration should be considered for relapsed primary spinal cord lymphomas similar to those with intracranial occurrence.
Indexed as
Identifiers
41243010What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.